A consolidated class action over the EpiPen, an epinephrine auto-injector used to treat severe allergic reactions, is headed to trial—although on a more truncated antitrust claim.

U.S. District Judge Daniel Crabtree in June tossed claims brought under the U.S. Racketeer Influenced and Corrupt Organizations Act and some of the antitrust allegations against Mylan Pharmaceuticals, which sold the EpiPen, a pen-like device that treats anaphylaxis, a potentially fatal condition caused by food allergies and insect bites.